| Range |
2 - 3 %
|
| Organism |
Human Homo sapiens |
| Reference |
Polyzoidis S, Koletsa T, Panagiotidou S, Ashkan K, Theoharides TC. Mast cells in meningiomas and brain inflammation. J Neuroinflammation. 2015 Sep 17 12 :170. doi: 10.1186/s12974-015-0388-3 p.1 right column top paragraphPubMed ID26377554
|
| Primary Source |
[8] Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg. 1985 Jan62(1):18-24 DOI: 10.3171/jns.1985.62.1.0018PubMed ID3964853
|
| Method |
Primary source abstract: "The rates of survival, tumor recurrence, and tumor progression were analyzed in 225 patients with meningioma who underwent surgery as the only treatment modality between 1962 and 1980. Patients were considered to have a recurrence if their studies verified a mass effect in spite of a complete surgical removal, whereas they were defined as having progression if, after a subtotal excision, there was clear radiological documentation of an increase in the size of their tumor." |
| Comments |
P.1 right column top paragraph: "The vast majority of meningiomas is graded as I and is benign [ref 5] with treatment consisting solely of surgical resection, which results in recurrence rates of 2–3 % following total resection [primary source]." |
| Entered by |
Uri M |
| ID |
117052 |